$ALGS


Aligos Therapeutics, Inc. (NASDAQ: ALGS), a clinical-stage biotechnology company, has discontinued development of ALG-020572, intended for the treatment of chronic hepatitis B (CHB). 

The Company had earlier ceased the development of ALG-010133, which targets chronic hepatitis B (CHB) in January 2022.

Here are 5 Things You Should Know about Aligos Therapeutics!

https://www.aviseanalytics.com/5-things-to-know-about-aligos-therapeutics/